Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Journal of Clinical Oncology · 20.07.2025 · 43 (21) · 2350-2360
DOI: 10.1200/jco-25-00746 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2025. Verfasst von Hani M Babiker und 22 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mayo Clinic, Jacksonville, FL.
- Virginia Mason Medical Center, Seattle, WA.
- The Cancer & Hematology Centers, Grand Rapids, MI.
- Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
- University of Kansas Cancer Center, Kansas City, KS.
- Changhai Hospital, Shanghai, People's Republic of China.
ORCID-Profile: Hani M Babiker, Anup Kasi, Javier Gallego, Andrea Bullock, Lucjan Wyrwicz, Arsen Osipov, Christelle de la Fouchardiere, Woojin Lee, Makoto Ueno, Eric Van Cutsem, Teresa Macarulla
Förderung
- NCI NIH HHS
Zitieren
APA
Babiker, H. M., Picozzi, V., Chandana, S. R., Melichar, B., Kasi, A., Gang, J., Gallego, J., Bullock, A., Chunyi, H., Wyrwicz, L., Hitre, E., Osipov, A., de la Fouchardiere, C., Ales, I., Dragovich, T., Lee, W., Feeney, K., Philip, P., Ueno, M., …, & PANOVA-3 Study Investigators (2025). Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. Journal of Clinical Oncology, 43(21), 2350-2360. https://doi.org/10.1200/jco-25-00746
Vancouver
Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, et al. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. Journal of Clinical Oncology. 2025;43(21):2350-2360. doi:10.1200/jco-25-00746
BibTeX
@article{Babiker2025,
author = {Babiker, Hani M and Picozzi, Vincent and Chandana, Sreenivasa R and Melichar, Bohuslav and Kasi, Anup and Gang, Jin and Gallego, Javier and Bullock, Andrea and Chunyi, Hao and Wyrwicz, Lucjan and Hitre, Erika and Osipov, Arsen and de la Fouchardiere, Christelle and Ales, Inmaculada and Dragovich, Tomislav and Lee, Woojin and Feeney, Kynan and Philip, Philip and Ueno, Makoto and Van Cutsem, Eric and Seufferlein, Thomas and Macarulla, Teresa and PANOVA-3 Study Investigators, PANOVA-3 Study Investigators},
title = {Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {21},
pages = {2350--2360},
doi = {10.1200/jco-25-00746}
}
EUVIMED